Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.

Related Articles

Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.

Oncotarget. 2017 Apr 29;:

Authors: Wang J, Shen Y, Wang J, Xue Y, Liao L, Thapa S, Ji K

Abstract
Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03-1.21, I2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.

PMID: 28515348 [PubMed - as supplied by publisher]

http://ift.tt/2pSrhdt